DOCSLIB.ORG

CHMP Assessment Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CHMP Assessment Report 15 November 2018 EMA/879617/2018 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Erleada International non-proprietary name: apalutamide Procedure No. EMEA/H/C/004452/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Administrative information Name of the medicinal product: Erleada Applicant: Janssen-Cilag International N.V. Turnhoutseweg 30 B-2340 Beerse BELGIUM Active substance: apalutamide International Non-proprietary Name: apalutamide Pharmaco-therapeutic group Endocrine therapy, anti-androgens (ATC Code): ATC code: L02BB05 Therapeutic indication(s): Erleada is indicated in adult men for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC) who are at high risk of developing metastatic disease (see section 5.1). Pharmaceutical form(s): Film-coated tablet Strength(s): 60 mg Route(s) of administration: Oral use Packaging: blister (PVC/PCTFE/alu) and bottle (HDPE) Package size(s): Blister: 112 tablets and 120 tablets Bottle: 120 tablets CHMP assessment report EMA/879617/2018 Page 2/139 Table of contents 1. Background information on the procedure .............................................. 8 1.1. Submission of the dossier ..................................................................................... 8 1.2. Steps taken for the assessment of the product ........................................................ 9 2. Scientific discussion .............................................................................. 10 2.1. Problem statement ............................................................................................. 10 2.1.1. Disease or condition ........................................................................................ 10 2.1.2. Epidemiology .................................................................................................. 11 2.1.3. Clinical presentation, diagnosis and stage/prognosis ............................................ 11 2.1.4. Management ................................................................................................... 11 2.2. Quality aspects .................................................................................................. 12 2.2.1. Introduction.................................................................................................... 12 2.2.2. Active Substance ............................................................................................. 12 2.2.3. Finished Medicinal Product ................................................................................ 16 2.2.4. Discussion on chemical, pharmaceutical and biological aspects.............................. 20 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects ...................... 21 2.2.6. Recommendations for future quality development ............................................... 21 2.3. Non-clinical aspects ............................................................................................ 21 2.3.1. Introduction.................................................................................................... 21 2.3.2. Pharmacology ................................................................................................. 21 2.3.3. Pharmacokinetics ............................................................................................ 24 2.3.4. Toxicology ...................................................................................................... 26 2.3.5. Ecotoxicity/environmental risk assessment ......................................................... 34 2.3.6. Discussion on non-clinical aspects ..................................................................... 36 2.3.7. Conclusion on the non-clinical aspects ............................................................... 39 2.4. Clinical aspects .................................................................................................. 39 2.4.1. Introduction.................................................................................................... 39 2.4.2. Pharmacokinetics ............................................................................................ 41 2.4.3. Pharmacodynamics .......................................................................................... 59 2.4.4. Discussion on clinical pharmacology ................................................................... 62 2.4.5. Conclusions on clinical pharmacology ................................................................. 63 2.5. Clinical efficacy .................................................................................................. 63 2.5.1. Dose response study........................................................................................ 63 2.5.2. Main study(ies) ............................................................................................... 63 2.5.3. Discussion on clinical efficacy .......................................................................... 100 2.5.4. Conclusions on the clinical efficacy .................................................................. 105 2.6. Clinical safety .................................................................................................. 106 2.6.1. Discussion on clinical safety ............................................................................ 124 2.6.2. Conclusions on the clinical safety .................................................................... 127 2.7. Risk Management Plan ...................................................................................... 128 2.8. Pharmacovigilance ........................................................................................... 132 2.9. New Active Substance ...................................................................................... 132 CHMP assessment report EMA/879617/2018 Page 3/139 2.10. Product information ........................................................................................ 132 2.10.1. User consultation ......................................................................................... 132 2.10.2. Labelling exemptions ................................................................................... 132 2.10.3. Additional monitoring ................................................................................... 133 3. Benefit-Risk Balance ........................................................................... 134 3.1. Therapeutic Context ......................................................................................... 134 3.1.1. Disease or condition ...................................................................................... 134 3.1.2. Available therapies and unmet medical need ..................................................... 134 3.1.3. Main clinical studies ....................................................................................... 134 3.2. Favourable effects ............................................................................................ 134 3.3. Uncertainties and limitations about favourable effects ........................................... 135 3.4. Unfavourable effects ......................................................................................... 135 3.5. Uncertainties and limitations about unfavourable effects ....................................... 136 3.6. Effects Table .................................................................................................... 136 3.7. Benefit-risk assessment and discussion ............................................................... 137 3.7.1. Importance of favourable and unfavourable effects ............................................ 137 3.7.2. Balance of benefits and risks .......................................................................... 138 3.7.3. Additional considerations on the benefit-risk balance ......................................... 138 3.8. Conclusions ..................................................................................................... 138 4. Recommendations ............................................................................... 138 CHMP assessment report EMA/879617/2018 Page 4/139 List of abbreviations ADR adverse drug reaction ADT androgen deprivation therapy AR androgen receptor ARV7 androgen receptor splice variant 7 AUC area under the plasma concentration-time curve BCS biopharmaceutical classification system BICR blinded independent central review BCRP breast cancer resistance protein BSA body surface area CHMP Committee for Medicinal Products for Human Use CI confidence interval CL/F apparent oral clearance Cmax maximum observed plasma concentration Cmin minimum observed plasma concentration CQA critical quality attributes CPP critical process parameters CRPC castration-resistant prostate cancer CTCAE Common Terminology Criteria for Adverse Events CYP Cytochrome P450 CPP Critical Process Parameter CQA Critical Quality Attribute DAD diode array detector DSC differential scanning calorimetry DVS dynamic vapour sorption ECOG PS Eastern Cooperative Oncology Group Performance Status EMA European Medicines Agency FACT-P Functional
Load more

Recommended publications
  • 210951Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210951Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review CDTL review is complete and has been added to the NDA/BLA Multidisciplinary Review and Evaluation. My recommendation for this application is regular approval. Reference ID: 4220973 --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- CHANA WEINSTOCK 02/14/2018 Reference ID: 4220973 NDA/BLA Multi-Disciplinary Review and Evaluation NDA 210951 Erleada (apalutamide) NDA/BLA Multi-disciplinary Review and Evaluation Application Type NDA Application Number(s) 210951 Priority or Standard Priority Submit Date(s) October 09, 2017 Received Date(s) October 10, 2017 PDUFA Goal Date April 10, 2018 Division/Office DOP1/OHOP Review Completion Date February 13, 2018 Established Name Apalutamide (Proposed) Trade Name Erleada Pharmacologic Class Androgen receptor inhibitor Code name JNJ-56021927, ARN-509 Applicant Aragon Pharmaceuticals, Inc., represented by Janssen Research & Development, LLC. Formulation(s) 60 mg tablets Dosing Regimen 240 mg Applicant
    [Show full text]
  • Preferred Drug List 4-Tier
    Preferred Drug List 4-Tier 21NVHPN13628 Four-Tier Base Drug Benefit Guide Introduction As a member of a health plan that includes outpatient prescription drug coverage, you have access to a wide range of effective and affordable medications. The health plan utilizes a Preferred Drug List (PDL) (also known as a drug formulary) as a tool to guide providers to prescribe clinically sound yet cost-effective drugs. This list was established to give you access to the prescription drugs you need at a reasonable cost. Your out- of-pocket prescription cost is lower when you use preferred medications. Please refer to your Prescription Drug Benefit Rider or Evidence of Coverage for specific pharmacy benefit information. The PDL is a list of FDA-approved generic and brand name medications recommended for use by your health plan. The list is developed and maintained by a Pharmacy and Therapeutics (P&T) Committee comprised of actively practicing primary care and specialty physicians, pharmacists and other healthcare professionals. Patient needs, scientific data, drug effectiveness, availability of drug alternatives currently on the PDL and cost are all considerations in selecting "preferred" medications. Due to the number of drugs on the market and the continuous introduction of new drugs, the PDL is a dynamic and routinely updated document screened regularly to ensure that it remains a clinically sound tool for our providers. Reading the Drug Benefit Guide Benefits for Covered Drugs obtained at a Designated Plan Pharmacy are payable according to the applicable benefit tiers described below, subject to your obtaining any required Prior Authorization or meeting any applicable Step Therapy requirement.
    [Show full text]
  • Erleada-Patient-Brochure.Pdf
    Table of Contents The path of prostate cancer. ......................................................... 3 How ERLEADA® (apalutamide) may help ........................................... 4 How androgens help fuel prostate cancer ......................................... 6 How to take ERLEADA®. .............................................................. 7 I’m hopeful. How to get ERLEADA® ................................................................ 8 I’m determined. Get help paying for your ERLEADA® ................................................. 9 I’m ready Important Safety Information ...................................................... 11 to fight my prostate cancer. Connecting with your healthcare team ........................................... 13 Questions to ask your doctor ....................................................... 13 What is ERLEADA®? ERLEADA® (apalutamide) is a prescription medicine used for the treatment of prostate cancer: • that has spread to other parts of the body and still responds to a medical or surgical treatment that lowers testosterone, OR • that has not spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone. It is not known if ERLEADA® is safe and effective in females. It is not known if ERLEADA® is safe and effective in children. IMPORTANT SAFETY INFORMATION Savings & Support Information • ERLEADA ® may cause serious side effects including: Heart disease, stroke, or mini-stroke, fractures and falls, and seizure 833-ERLEADA (833-375-3232)
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men with Localized Prostate Cancer Pre-Prostatectomy
    CC Protocol Number: 9628 PI: Michael T. Schweizer, MD Neoadjuvant therapy in high-risk Prostate Cancer Protocol Version: 4.0; March 23, 2018 A Phase II neoadjuvant study of Apalutamide, abiraterone acetate, prednisone, degarelix and indomethacin in men with localized prostate cancer pre-prostatectomy University of Washington / Seattle Cancer Care Alliance Cancer Consortium Protocol Number: 9628 IND Number: 129692 ClinicalTrials.gov: NCT02849990 Protocol Version Number: 4.0 March 23, 2018 Sponsor-Investigator / Principal Investigator: Site: Michael T. Schweizer, MD University of Washington / Seattle University of Washington / Seattle Cancer Care Alliance Cancer Care Alliance Email: [email protected] Medication Support Provided by: Biostatistician: Janssen Scientific Affairs, LLC Roman Gulati Fred Hutchinson Cancer Research Center Email: [email protected] 1 CC Protocol Number: 9628 PI: Michael T. Schweizer, MD Neoadjuvant therapy in high-risk Prostate Cancer Protocol Version: 4.0; March 23, 2018 Title: A Phase II neoadjuvant study of Apalutamide, abiraterone acetate, prednisone, degarelix and indomethacin in men with localized prostate cancer pre-prostatectomy Objectives: To assess the pathologic effects of 3-months (12 weeks) of neoadjuvant apalutamide, abiraterone acetate, degarelix and indomethacin in men with localized prostate cancer pre-prostatectomy. Study Design: Open label, single-site, Phase II study designed to determine the pathologic effects that 3-months (12 weeks) of neoadjuvant therapy has on men with localized prostate cancer. Primary Center: University of Washington/Seattle Cancer Care Alliance Participating Institutions: 1 site in the United States. Medication Support: Janssen Scientific Affairs, LLC Timeline: This study is planned to complete enrollment in one year, with 2-years of additional follow up following accrual of the last subject.
    [Show full text]
  • AMENDMENT SUMMARY Castration-Resistant Prostate Cancer
    AMENDMENT SUMMARY Castration-Resistant Prostate Cancer (CRPC) Guideline Amendment 2018 Amendment Panel Dr. William Lowrance (Chair), Dr. Michael Cookson, Dr. William Oh, Dr. David Jarrard, Dr. Matthew Resnick Purpose: One of the first clinical presentations of CRPC occurs in a patient with a rising PSA despite medical or surgical castration. For the purposes of this Guideline, these patients are Index Patient 1. This is typically defined as a patient with a rising PSA and no radiologic evidence of metastatic prostate cancer. The Prostate Cancer Clinical Trials Working Group 2 (PCWG2) defines PSA only failure as a rising PSA that is greater than 2ng/mL higher than the nadir; the rise has to be at least 25% over nadir, and the rise has to be confirmed by a second PSA at least three weeks later. In addition, the patient is required to have castrate levels of testosterone (less than 50 ng/dL) and no radiographic evidence of metastatic disease. These patients represent a relatively common clinical presentation and the earliest clinical manifestation of castration resistance. Until recently, no agent had been shown to demonstrate significant benefits in large Phase 3 trials in the non-metastatic CRPC patient population. Updated Methodology A systematic review and meta-analysis of the published literature was conducted using controlled vocabulary supplemented with keywords relating to the relevant concepts of prostate cancer and castration resistance. The original search strategy was developed and executed by reference librarians and methodologists to create a final evidence report limited to English-language, peer-reviewed literature published between January 1996 and February 2013.
    [Show full text]
  • Australian Public Assessment Report for Apalutamide
    Australian Public Assessment Report for Apalutamide Proprietary Product Name: Erlyand/Janssen Apalutamide Sponsor: Janssen-Cilag Pty Ltd March 2019 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications. • An AusPAR is a static document; it provides information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Apalutamide) Tablets, for Oral Use Initial U.S
    Fractures occurred in patients receiving ERLEADA. Evaluate patients HIGHLIGHTS OF PRESCRIBING INFORMATION for fracture risk and treat patients with bone-targeted agents according to These highlights do not include all the information needed to use established guidelines. (5.2) ERLEADA safely and effectively. See full prescribing information for ERLEADA. Falls occurred in patients receiving ERLEADA with increased incidence in the elderly. Evaluate patients for fall risk. (5.3) ERLEADA® (apalutamide) tablets, for oral use Initial U.S. Approval – 2018 Seizure occurred in 0.4% of patients receiving ERLEADA. Permanently discontinue ERLEADA in patients who develop a seizure during --------------------------RECENT MAJOR CHANGES---------------------------- treatment. (5.4) Indications and Usage (1) 09/2019 Warnings and Precautions (5) 09/2019 Embryo-Fetal Toxicity: ERLEADA can cause fetal harm. Advise males with female partners of reproductive potential to use effective contraception. (5.5, 8.1, 8.3) -----------------------------INDICATIONS AND USAGE--------------------------- ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients with ------------------------------ADVERSE REACTIONS------------------------------- metastatic castration-sensitive prostate cancer. (1) The most common adverse reactions (≥10%) are fatigue, arthralgia, rash, non-metastatic castration-resistant prostate cancer. (1) decreased appetite, fall, weight decreased, hypertension, hot flush, diarrhea, and fracture. (6.1) ------------------------DOSAGE
    [Show full text]
  • Cancer Biology – Sbb1605 Cancer: a Historic Perspective
    SCHOOL OF BIO AND CHEMICAL ENGINEERING DEPARTMENT OF BIOTECHNOLOGY UNIT – I– CANCER BIOLOGY – SBB1605 CANCER: A HISTORIC PERSPECTIVE Since the earliest medical records were kept, cancer as a disease has been described in the history of medicine. The earliest known descriptions of cancer appear in seven papyri, discovered and deciphered late in the 19th century. They provided the first direct knowledge of Egyptian medical practice. Two of them, known as the "Edwin Smith" and "George Ebers" papyri, contain descriptions of cancer written around 1600 B.C., and are believed to date from sources as early as 2500 B.C. The Smith papyrus describes surgery, while the Ebers' papyrus outlines pharmacological, mechanical, and magical treatments. Based on the information recorded on papyri and hieroglyphic inscriptions, ancient Egyptians were able to distinguish benign tumors from malignant tumors. They were also able to use different treatments, including surgery, and other various modes of medicine. Following the decline of Egypt, the next chapters of medical and scientific history were written in Greece and Rome. The great doctors Hippocrates and Galen dominated medical thought for 1500 years. They lifted medicine out of the realms of magic, superstition, and religion. Hippocrates and Galen defined disease as a natural process, and based treatment on observation and experience. Cancers were identified, with warnings against treatment of the more severe forms. Hippocrates is credited with naming "cancer" as "karkinoma" (carcinoma) because a tumor looked like a "crab" ("karkinoma" is Greek for "crab") in that there is a central body to a tumor and the tumor extension appeared as the legs of the "crab".
    [Show full text]
  • Androgen Receptor Signaling Pathway in Prostate Cancer: from Genetics to Clinical Applications
    cells Review Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 1, 2, 2, Gaetano Aurilio y, Alessia Cimadamore y, Roberta Mazzucchelli y, Antonio Lopez-Beltran 3 , Elena Verri 1, Marina Scarpelli 2, Francesco Massari 4 , Liang Cheng 5 , Matteo Santoni 6 and Rodolfo Montironi 2,* 1 Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; [email protected] (G.A.); [email protected] (E.V.) 2 Section of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, 60126 Ancona, Italy; a.cimadamore@staff.univpm.it (A.C.); r.mazzucchelli@staff.univpm.it (R.M.); [email protected] (M.S.) 3 Department of Surgery, Cordoba University Medical School, 14071 Cordoba, Spain; [email protected] 4 Division of Oncology, S. Orsola-Malpighi Hospital, 40138 Bologna, Italy; [email protected] 5 Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA; [email protected] 6 Oncology Unit, Macerata Hospital, 62100 Macerata, Italy; [email protected] * Correspondence: r.montironi@staff.univpm.it; Tel.: +39-071-5964830; Fax: +39-071-889985 These authors contributed equally to this work. y Received: 11 November 2020; Accepted: 8 December 2020; Published: 10 December 2020 Abstract: Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is generally the first therapy adopted. However, the patient’s response to androgen ablation therapy is variable, and 20–30% of PCa cases become castration resistant (CRPCa).
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 32, No. 4, 2018 WHO Drug Information Contents ICDRA ATC/DDD classification 509 18th International Conference of Drug Regulatory 551 ATC/DDD classification (temporary) Authorities (ICDRA) Recommendations 556 ATC/DDD classification (final) Consultation documents International Nonproprietary Names (INN) 519 The International Pharmacopoeia 519 Revision of the monograph on ethinylestradiol 530 Polymorphism 559 List N° 120 of Proposed International Nonproprietary 538 Revision of the monograph on levofloxacin 546 Revision of the monograph on levofloxacin tablets Names (INN) for Pharmaceutical Substances Abbreviations and websites CHMP Committee for Medicinal Products for Human Use (EMA) EMA European Medicines Agency (www.ema.europa.eu) European Union EU FDA U.S. Food and Drug Administration (www.fda.gov) Health Canada Federal department responsible for health product regulation in Canada (www.hc-sc.gc.ca) HPRA Health Products Regulatory Authority, Ireland (www.hpra.ie ) HSA Health Sciences Authority, Singapore (www.hsa.gov.sg) ICDRA International Conference of Drug Regulatory Authorities ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use IGDRP (www.ich.org) International Generic Drug Regulators Programme (https://www.igdrp.com) MHLW Ministry of Health, Labour and Welfare, Japan MHRA Medicines and Healthcare Products Regulatory Agency, United Kingdom (www.mhra.gov.uk) Medsafe New Zealand Medicines and Medical Devices Safety Authority (www.medsafe.govt.nz) Ph. Int The International Pharmacopoeia (http://apps.who.int/phint/) Pharmacovigilance Risk Assessment Committee (EMA) PRAC Pharmaceuticals and Medical Devices Agency, Japan (www.pmda.go.jp/english/index.htm) PMDA Swissmedic Swiss Agency for Therapeutic Products (www.swissmedic.ch) TGA Therapeutic Goods Administration, Australia (www.tga.gov.au) U.S.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]